Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OZ101
- Development stage
- Unknown
- Lead developer
- OzStar Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OZ101 is an oral prebiotic tablet formulation of oligofructose, a naturally derived fiber, being developed by OzStar Therapeutics and GlyConMedics. It is designed as an add-on therapy for patients with type 2 diabetes mellitus who are currently treated with sulphonylureas. The drug's mechanism involves modulating the gut microbiome to address dysbiosis, which in turn improves glycaemic control and enhances the durability of sulphonylurea treatment by supporting pancreatic beta-cell function. OZ101 has completed a 24-week pilot dose-ranging study and has received regulatory support for Phase 2 clinical development.
- Other names
- oligofructose
Beyond the preview
Go deeper on OZ101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OZ101.